Insulin pump denial: how to appeal a denied insulin pump (CSII)

Medicare covers continuous subcutaneous insulin infusion (an insulin pump) as durable medical equipment under National Coverage Determination 280.14. A patient qualifies through one of two documented paths: a fasting C-peptide level showing insulinopenia, or being beta-cell-autoantibody positive — plus the remaining criteria in the NCD. Continued coverage requires the treating practitioner to see the patient at least every three months. Most denials trace to one of those facts being absent from the record rather than to a true exclusion, which is what makes them appealable. Commercial plans set their own prior-authorization criteria, so a commercial denial usually turns on documentation or a preferred-pump step.

How Insulin pump is covered

Under NCD 280.14, an insulin pump is covered as DME for a patient who meets one of two qualifying paths and the remaining criteria: a fasting C-peptide level demonstrating insulinopenia (defined as a fasting C-peptide at or below 110% of the lower limit of the lab’s normal range, with a concurrently drawn fasting glucose at or below 225 mg/dL), or documentation that the patient is beta-cell-autoantibody positive. For a patient with renal insufficiency, the C-peptide threshold is adjusted. Continued coverage of the pump and supplies requires a visit with the treating practitioner at least every three months. The External Infusion Pumps LCD (L33794) governs the DME documentation. Commercial plans cover insulin pumps on their own medical-policy criteria, usually through prior authorization and a contracted DME supplier.

Why Insulin pump claims get denied

• Medicare: neither qualifying path documented — no C-peptide showing insulinopenia and no record of beta-cell-autoantibody positivity.
• Medicare: the C-peptide was drawn without the concurrent fasting glucose at or below 225 mg/dL, so the result wasn’t considered valid.
• Medicare: the every-three-months visit with the treating practitioner wasn’t documented, so ongoing coverage lapsed.
• The pump or supplies were billed through a non-contracted DME supplier, or a coding/billing error.
• Commercial: the plan’s own prior-authorization criteria weren’t met or weren’t documented, or a preferred-pump step applies.

Is a Insulin pump denial worth appealing?

How to appeal a Insulin pump denial

1. 1

   Pin the exact criterion the denial cites

   Separate a Medicare NCD/LCD denial from a commercial prior-auth denial — they apply different criteria, and the appeal has to answer the one actually used.

2. 2

   Document the qualifying path

   For Medicare, attach the valid fasting C-peptide (with the concurrent fasting glucose) or the autoantibody result, plus the every-three-months visit note that keeps coverage active.

3. 3

   For commercial plans, map the chart to the policy

   Tie the diabetes-management history and clinical rationale to each element the insurer’s own insulin-pump policy requires.

4. 4

   Escalate on the right ladder

   A Medicare Advantage pump denial follows the MA appeal process; Original Medicare follows the five-level process; a commercial denial goes through internal appeal and then external review.

Insulin pump — frequently asked

FDA-approved indications and payer prior-authorization criteria are paraphrased for plain-language reference, not reproduced verbatim, and vary by plan. This is general information, not medical, legal, or coverage advice — confirm against the current FDA label, the plan's policy, and the patient's benefit documents.